Stockreport

Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF Interim real-world data reinforces effectiveness and tolerability of mogamulizumab for mycosis fungoides (MF) or Sézary Syndrome (SS) in routine clinical practice GAL [Read more]